CYP2C8: A Versatile Enzyme for Drug Targeting and Biomarker (G1558)

Target Name: CYP2C8

NCBI ID: G1558

CYP2C8

CYP2C8: A Versatile Enzyme for Drug Targeting and Biomarker

CYP2C8, also known as monooxygenase CYP2C8, is a enzyme located in the cytoplasm of many eukaryotic cells. This enzyme is involved in the metabolism of various drugs, including many statins, benzodiazepines, and opioids. It is a key enzyme in the liver's metabolism of these drugs, and its activity can be affected by various factors, including genetic variations and drugs that inhibit its function.

CYP2C8 is a monooxygenase, which means it produces reactive oxygen species (ROS) during its metabolism of drugs. These ROS can interact with other cellular components and contribute to various cellular processes, including cell signaling, DNA damage, and cell death. The cytoplasm of many eukaryotic cells contain a high concentration of ROS, which can damage cell components and contribute to cellular dysfunction and death.

CYP2C8 is a versatile enzyme that can be targeted by various drug classes. Its activity in drug metabolism makes it an attractive drug target for the development of new pharmaceuticals, including statins, benzodiazepines, and opioids. The ability of CYP2C8 to generate ROS during its metabolism of drugs also makes it a potential biomarker for drug-induced cellular damage.

One of the challenges in targeting CYP2C8 is its location in the cytoplasm, which makes it difficult to reach with small molecules. However, various techniques, such as inhibition of CYP2C8 by small molecule inhibitors or genetic modification of the enzyme, have been developed to increase the accessibility of the enzyme to small molecules.

In addition to its potential as a drug target, CYP2C8 is also a potential biomarker for drug-induced cellular damage. Many drugs can cause cellular dysfunction and damage, including muscle damage, neurotoxicity, and cardiotoxicity. The cytoplasm of many eukaryotic cells contain a high concentration of ROS, which can contribute to cellular dysfunction and death. By targeting CYP2C8, researchers can study the mechanisms of drug-induced cellular damage and develop new treatments.

CYP2C8 is also involved in the metabolism of many other drugs, including many opioids, benzodiazepines, and other drugs used for pain relief. Its activity in these drug classes makes it an important enzyme in the liver's metabolism of these drugs. However, the metabolism of these drugs can also contribute to the development of drug-induced cellular damage and increase the risk of adverse effects.

In conclusion, CYP2C8 is a versatile enzyme that can be targeted by various drug classes for the development of new pharmaceuticals and biomarkers. Its location in the cytoplasm and its involvement in the metabolism of many drugs make it an attractive target for researchers. Further research is needed to fully understand the mechanisms of its activity and its potential as a drug target and biomarker.

Protein Name: Cytochrome P450 Family 2 Subfamily C Member 8

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed:7574697, PubMed:15766564, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed:11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed:14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed:26427316)

The "CYP2C8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2C8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets